Any current/future new fundraising through debt or equity?

No indication of any immediate or planned fundraising through equity or debt was mentioned. The company is currently generating healthy operating cash flow (Rs. 129 crores last year). It prefers using debt financing for equipment purchases rather than shareholder cash. Cash deployment is conservative, focusing on prudent capital allocation without large CAPEX or acquisitions. International expansion is planned with a modest initial CAPEX allocation of Rs. 20 crores across three geographies. No mention of equity dilution or fresh share issuance; existing ESOPs are non-cash and non-dilutive in t

Any current/future capex/capital investment/strategic investment?

FY23 CAPEX was Rs. 41 crores, mainly spent on setting up 6 regional labs (Rs. 5-6 crores each) and 2 new nuclear centers. FY24 CAPEX forecast is around Rs. 40 crores, including Indian operations (Goa lab and a couple of satellite labs) and some nuclear lab shifts. Rs. 20 crores allocated for international expansion in FY24, primarily for Africa, Middle East, and Southeast Asia markets, expected to be spent mostly in Q3 and Q4. International expansion CAPEX is modest (~Rs. 6-7 crores per geography), still at MoU stage; minimal material impact expected on EBITDA or balance sheet in near term. No

Future growth expectations in earnings/operating earnings/profits/EPS?

Growth expected to stabilize after recent expansion of 10 operational centers, with 2 more centers likely to become operational in H2 FY24. Volume growth expected around 10-12% annually from new centers and organic business growth. Pricing is largely stabilized; price increases are difficult in the current market. Nuclear business growth seen as more of an annuity, with fiscal '23 growth partially recovery-driven; similar high growth rates are not anticipated going forward. International expansion planned but small investments (around Rs. 20 crores across 3 geographies); no material EBITDA or

Current/ Expected Orderbook/ Pending Orders?

Thyrocare has 10 operational centers currently. There are issues at some centers; management expects to get 2 more centers operational in the second half of the year. Growth from getting these 2 centers operational is expected to add approximately a 10% volume impact in H2. Pricing is largely stabilized, with no expectation of significant price hikes. The business moving forward is expected to be more organic with a steady 10-12% pure scan volume growth. No explicit mention of a large backlog or outstanding orderbook was given; focus is on stabilizing and organic expansion rather than aggressi

Thyrocare Technologies LtdQ4 FY23Healthcare Services

Thyrocare Technologies Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹534P/E: 49.9Market Cap: ₹9.0K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

- Growth is expected to stabilize going forward; the high growth rates of the past are not anticipated to continue next year. - Two more non-operational centers (out of a base of 10) are expected to become operational in the second half of the year, potentially adding ~10% volume impact. - Pricing is largely stabilized with limited scope for further price increases in the current market. - The business is seen as more organic and annuity in nature, with anticipated pure scan volume growth around 10-12% annually. - Non-COVID volume growth has been strong (39% YoY), but this high growth rate is also expected to moderate. - International expansion is in early stages with Rs. 20 crores CAPEX allocated across 3 geographies; this is not expected to materially impact revenue in the short term. - Radiology business shows strong recovery and growth (47% YoY). Overall, expect moderate organic volume growth with stable pricing and gradual expansion.

Margin guidance

Category 3

Growth expected to stabilize after recent expansion of 10 operational centers, with 2 more centers likely to become operational in H2 FY24.
Volume growth expected around 10-12% annually from new centers and organic business growth.
Pricing is largely stabilized; price increases are difficult in the current market.
Nuclear business growth seen as more of an annuity, with fiscal '23 growth partially recovery-driven; similar high growth rates are not anticipated going forward.
International expansion planned but small investments (around Rs. 20 crores across 3 geographies); no material EBITDA or P&L impact expected in short term.
CAPEX limited, focused on international expansion and no large acquisitions planned.
Dividend policy to be maintained barring major changes or acquisition opportunities.
EBITDA margin stable (~29-31%) with improving operating cash flows (Rs. 129 crores free cash flow in FY23).
Overall, expect organic growth with EBITDA and EPS growth moderate and steady rather than high double-digit expansion.

See what Thyrocare Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No indication of any immediate or planned fundraising through equity or debt was mentioned.
The company is currently generating healthy operating cash flow (Rs. 129 crores last year).
It prefers using debt financing for equipment purchases rather than shareholder cash.
Cash deployment is conservative, focusing on prudent capital allocation without large CAPEX or acquisitions.
International expansion is planned with a modest initial CAPEX allocation of Rs. 20 crores across three geographies.
No mention of equity dilution or fresh share issuance; existing ESOPs are non-cash and non-dilutive in the short term.
Management emphasizes returning cash to shareholders via dividends rather than retaining cash for aggressive growth or fundraising.

Order book

Yes

Thyrocare has 10 operational centers currently.
There are issues at some centers; management expects to get 2 more centers operational in the second half of the year.
Growth from getting these 2 centers operational is expected to add approximately a 10% volume impact in H2.
Pricing is largely stabilized, with no expectation of significant price hikes.
The business moving forward is expected to be more organic with a steady 10-12% pure scan volume growth.
No explicit mention of a large backlog or outstanding orderbook was given; focus is on stabilizing and organic expansion rather than aggressive scaling or order accumulation.

See what Thyrocare Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

FY23 CAPEX was Rs. 41 crores, mainly spent on setting up 6 regional labs (Rs. 5-6 crores each) and 2 new nuclear centers.
FY24 CAPEX forecast is around Rs. 40 crores, including Indian operations (Goa lab and a couple of satellite labs) and some nuclear lab shifts.
Rs. 20 crores allocated for international expansion in FY24, primarily for Africa, Middle East, and Southeast Asia markets, expected to be spent mostly in Q3 and Q4.
International expansion CAPEX is modest (~Rs. 6-7 crores per geography), still at MoU stage; minimal material impact expected on EBITDA or balance sheet in near term.
No plans for large acquisitions; company prefers debt financing for equipment to preserve shareholder cash.
Dividend policy remains aggressive unless a lucrative growth opportunity arises.

Track Thyrocare Technologies Ltd — get its next earnings analysis in your feed

How does Thyrocare Technologies Ltd rank vs peers in Healthcare Services?

Pro feature

ThisThyrocare Technologies Ltd

Rev 2Mar 3

See where Thyrocare Technologies Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Thyrocare Technologies Ltd rank in Healthcare Services?

Compare Thyrocare Technologies Ltd against every Healthcare Services company (Q4 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Thyrocare Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →